BMS986260
CAS No. 2001559-19-7
BMS986260 ( —— )
Catalog No. M22636 CAS No. 2001559-19-7
BMS-986260 is a selective, and orally bioavailable TGFβR1 inhibitor(IC50 = 1.6 nM). BMS-986260?demonstrated functional activity in multiple TGFβ-dependent cellular assays, excellent kinome selectivity, favorable pharmacokinetic properties, and curative in vivo efficacy in combination with anti-PD-1 antibody in murine colorectal cancer (CRC) models.?
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 178 | In Stock |
|
10MG | 264 | In Stock |
|
25MG | 448 | In Stock |
|
50MG | 626 | In Stock |
|
100MG | 885 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBMS986260
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMS-986260 is a selective, and orally bioavailable TGFβR1 inhibitor(IC50 = 1.6 nM). BMS-986260?demonstrated functional activity in multiple TGFβ-dependent cellular assays, excellent kinome selectivity, favorable pharmacokinetic properties, and curative in vivo efficacy in combination with anti-PD-1 antibody in murine colorectal cancer (CRC) models.?
-
DescriptionBMS-986260 is a selective, and orally bioavailable TGFβR1 inhibitor(IC50 = 1.6 nM). BMS-986260?demonstrated functional activity in multiple TGFβ-dependent cellular assays, excellent kinome selectivity, favorable pharmacokinetic properties, and curative in vivo efficacy in combination with anti-PD-1 antibody in murine colorectal cancer (CRC) models.?Since daily dosing of TGFβR1 inhibitors is known to cause class-based cardiovascular (CV) toxicities in preclinical species, a dosing holiday schedule in the anti-PD-1 combination efficacy studies was explored.?An intermittent dosing regimen of 3 days on and 4 days off allowed mitigation of CV toxicities in one month dog and rat toxicology studies and also provided similar efficacy as once daily dosing.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorTGFβR1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2001559-19-7
-
Formula Weight382.07
-
Molecular FormulaC18H12ClFN6O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOCCn1cnc(c1-c1ccc2ncc(C#N)n2n1)-c1ccc(F)c(Cl)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent[J]. ACS Medicinal Chemistry Letters, 2020, 11(2):172-178.
molnova catalog
related products
-
Lenacapavir
Lenacapavir is a potent capsid-targeting inhibitor of HIV replication. Lenacapavir shows anti-HIV activity with an EC50 of 100 pM in MT-4 cells.
-
2-Naphthol
2-Naphthol, or β-naphthol, is a fluorescent colorless crystalline solid with the formula C10H7OH.
-
NS13001
NS13001 is a potent, selective, orally active allosteric positive modulator of SK channels (small conductance calcium-activated potassium channels).